Correlation of matrix metalloproteinase-2, −9, tissue inhibitor-1 of matrix metalloproteinase and CD44 variant 6 in head and neck cancer metastasis

Xu, Yaping; Zhao, Xue-qun; Sommer, Karen; Moubayed, Pierre

doi:10.1631/jzus.2003.0491

Cited by 15 publications

(8 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Loss of BRCA2 correlates with a significant decrease in survival time, and certain chromosomal deletions (i.e., 10q and 14q) were found to be associated with poor prognosis (33)(34)(35). Increased gene expression [i.e., NBS1, FGFR, Ki-67, HER2, matrix metalloproteinase 2 (MMP2) and MMP9, and cyclin D1] has been shown to indicate the aggressiveness of the disease (36)(37)(38)(39)(40)(41), and elevated alpha B-crystallin expression has been found to be a more sensitive marker for HNSCC recurrence than the combination of plasminogen activator inhibitor-1 (PAI-1) and urokinase-type plasminogen activator (42). However, there is still not a DNA methylation marker for poor prognosis (12).…”

Section: Discussionmentioning

confidence: 99%

Tumor Suppressor Activity of CCAAT/Enhancer Binding Protein α Is Epigenetically Down-regulated in Head and Neck Squamous Cell Carcinoma

Bennett¹,

Hackanson

Smith

et al. 2007

Cancer Research

View full text Add to dashboard Cite

Tumor suppressor CCAAT enhancer binding protein a (C/EBPa) is a transcription factor involved in cell cycle control and cellular differentiation. In a recent study, microarray expression profiling on head and neck squamous cell carcinoma (HNSCC) samples identified significant C/EBPa down-regulation, correlating with poor prognosis. However, the mechanisms of C/EBPa down-regulation remained elusive. C/EBPa has been previously found to provide an antiproliferative role in lung cancer, and our laboratory showed that its down-regulation involves epigenetic mechanisms. This prompted us to investigate the involvement of epigenetics in down-regulating C/EBPa in HNSCC. Here, we show that C/EBPa is down-regulated in HNSCC by loss of heterozygosity and DNA methylation, but not by gene mutation. We found a consistently methylated upstream regulatory region (À1,399 bp to À1,253 bp in relation to the transcription start site) in 68% of the HNSCC tumor samples, and DNA demethylation using 5-aza-2 ¶-deoxycytidine treatment was able to significantly restore C/EBPa mRNA expression in the HNSCC cell lines we tested. In addition, C/EBPa overexpression in a HNSCC cell line (SCC22B) revealed its ability to provide tumor suppressor activity in HNSCC in vitro and in vivo. In conclusion, we showed for the first time not only that C/EBPa has tumor suppressor activity in HNSCC, but also that it is down-regulated by DNA promoter methylation. [Cancer Res 2007;67(10):4657-64]

show abstract

Section: Discussionmentioning

confidence: 99%

Tumor Suppressor Activity of CCAAT/Enhancer Binding Protein α Is Epigenetically Down-regulated in Head and Neck Squamous Cell Carcinoma

Bennett¹,

Hackanson

Smith

et al. 2007

Cancer Research

View full text Add to dashboard Cite

show abstract

“…The features of the 19 eligible studies are listed in Table 1; 1 study was from each of the following countries: Spain (Esteban et al 2005),Turkey (Yuce et al 2011), Italy (Staibano et al 2007), Finland (Kokko et al 2011), and the USA (Janisiewicz et al 2012), two studies were from Japan (Kawano et al 2004;Uwa et al 2011), and 12 were from China (Song et al 1999;Wang et al 2000;Zhao et al 2003;Xu et al 2003;Wang et al 2004;Qiu et al 2006;Huang et al 2007;Lu et al 2008;Ma et al 2009;Gao 2009;Guo et al 2009;Lu et al 2011). Three studies focused on pharyngeal cancer, 14 focused on laryngeal cancer, and 2 studied both laryngeal and pharyngeal cancer.…”

Section: Study Characteristicsmentioning

confidence: 99%

“…With respect to pharyngolaryngeal cancer, the relationships between CD44 and clinicopathological features and prognosis were still controversial mainly because of the limited patient numbers of independent reports (Xu et al 2003;Esteban et al 2005). Here we performed a systematic review of the published studies and aimed to investigate the prediction value of CD44 in clinical features and prognosis of pharyngolaryngeal cancer.…”

Section: Introductionmentioning

confidence: 99%

CD44 Expression Is Predictive of Poor Prognosis in Pharyngolaryngeal Cancer: Systematic Review and Meta-Analysis

Chai

Liu

Wang

et al. 2014

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

Pharyngolaryngeal cancer is one of the most common head and neck cancer worldwide, and the early diagnosis and prognosis prediction are still difficult because of lacking in reliable cell markers. Although the expression of CD44 has been reported to correlate with poor prognosis of pharyngolaryngeal cancer in most literatures, some controversies still exist. Since the limited patient numbers within independent studies, here we performed a meta-analysis to clarify the correlations between CD44 expression and clinicopathological features and prognosis in pharyngolaryngeal cancer. A search of PubMed, ISI Web of Science and China National Knowledge Infrastructure databases (up to June 2013) was performed. Nineteen studies with 1,405 patients met the inclusion criteria. The expression of pan-CD44, including all variant isoforms, was detected in 58.0% (14.1-79.2%) specimens, while CD44-v6 (variant isoform 6 of CD44) was expressed in 54.8% (12-79.2%). In pooled analysis, CD44 expression was significantly associated with larger tumor size (T category, RR (relative risk) = 1.21, 95% CI: 1.01-1.46), lymph nodes metastasis (N category, RR = 1.94, 95% CI: 1.38-2.73) and poor prognosis [3-year overall survival (OS): RR = 0.70, 95% CI: 0.53-0.91; 5-year OS: RR = 0.66, 95% CI: 0.66-0.94]. In the stratified analysis of CD44 isoforms, high expression of CD44-v6 was related with a poor 5-year OS rate (RR = 0.53, 95% CI: 0.37-077). We propose that CD44 expression is associated with tumor size, lymph node metastasis, and poor prognosis in pharyngolaryngeal cancer patients.

show abstract

“…CD44 is one of the major molecules found at the leading edge or invadopodia of invading cancer cells. Specifically its variant form CD44v6 [43,44], the form found in most metastatic carcinomas, is associated with MMP-9, in a concerted effort to degrade the extracellular matrix, invade the surrounding stroma, and mobilize the cancer cells [45]. Oncogenic expression of the microRNA miR-155 has recently been shown to be upregulated in hepatocellular carcinoma (HCC) by S100A4, secreted by liver cancer-associated MSCs.…”

mentioning

confidence: 99%

Involvement of Mesenchymal Stem Cells in Cancer Progression and Metastases

Chang¹,

Schwertschkow²,

Nolta³

et al. 2015

CCDT

View full text Add to dashboard Cite

Mesenchymal stem/stromal cells (MSCs) are known to be the helpers for the healing of tissue damage, often referred to as ambulatory cells. However, MSCs are also recruited by cancer cells to similarly aid in tumor growth and progression. In this review, some of the key steps in cancer progression and metastases are described including the various steps in which MSCs participate and may play important roles. MSCs aid in cancer cells' ability to evade immune attack, while promoting tumor angiogenesis, even being counter-acting against chemotherapeutics and other drugs used to fight various cancers. Furthermore, MSCs participate in many of the crucial steps in invasion and metastasis, including stimulating the epithelial-mesenchymal transition (EMT) and induction of stem-like properties that allow cancer stem cells to increase their survivability through the circulation. These steps are described in detail. Differences between circulating tumor cells (CTCs) and cancer stem cells (CSCs) are discussed, along with descriptions of the formation of a pre-metastatic niche, the role of exosomes from both cancer cells and MSCs in metastasis and tumor reseeding (self-seeding). More and more, MSCs are being proposed as a promising tumor targeting drug-delivery tool. In order to fulfill this promise, further understanding of the precise roles that MSCs play in the process of cancer metastases must be achieved, in attempting to create remedies that will improve the outcome of available therapeutics.

show abstract

Correlation of matrix metalloproteinase-2, −9, tissue inhibitor-1 of matrix metalloproteinase and CD44 variant 6 in head and neck cancer metastasis

Cited by 15 publications

References 20 publications

Tumor Suppressor Activity of CCAAT/Enhancer Binding Protein α Is Epigenetically Down-regulated in Head and Neck Squamous Cell Carcinoma

Tumor Suppressor Activity of CCAAT/Enhancer Binding Protein α Is Epigenetically Down-regulated in Head and Neck Squamous Cell Carcinoma

CD44 Expression Is Predictive of Poor Prognosis in Pharyngolaryngeal Cancer: Systematic Review and Meta-Analysis

Involvement of Mesenchymal Stem Cells in Cancer Progression and Metastases

Contact Info

Product

Resources

About